Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Wungki Park"'
Autor:
Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M. Coussens, Daniel D. De Carvalho, David G. DeNardo, Jérôme Galon, Howard L. Kaufman, Tomas Kirchhoff, Michael T. Lotze, Jason J. Luke, Andy J. Minn, Katerina Politi, Leonard D. Shultz, Richard Simon, Vésteinn Thórsson, Joanne B. Weidhaas, Maria Libera Ascierto, Paolo Antonio Ascierto, James M. Barnes, Valentin Barsan, Praveen K. Bommareddy, Adrian Bot, Sarah E. Church, Gennaro Ciliberto, Andrea De Maria, Dobrin Draganov, Winson S. Ho, Heather M. McGee, Anne Monette, Joseph F. Murphy, Paola Nisticò, Wungki Park, Maulik Patel, Michael Quigley, Laszlo Radvanyi, Harry Raftopoulos, Nils-Petter Rudqvist, Alexandra Snyder, Randy F. Sweis, Sara Valpione, Roberta Zappasodi, Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, Alessandra Cesano, Francesco M. Marincola, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-23 (2019)
Abstract Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include th
Externí odkaz:
https://doaj.org/article/864f25d06ad04690a4ef2014434f0547
Autor:
Muhammad Husnain, Wungki Park, Juan Carlos Ramos, Thomas E. Johnson, Joseph Chan, Arvind Dasari, Raja Mudad, Peter J. Hosein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Background Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs cl
Externí odkaz:
https://doaj.org/article/28886b086c754a4c8c3f2ef2e1f0bcbf
Autor:
Diana Saravia, Andrew J. Plodkowski, Annapaola Mariniello, Benjamin Besse, Lizza E.L. Hendriks, Maria Lucia Reale, Fabrizio Tabbò, Gilberto Lopes, Lydie Cassard, Anne-Marie C. Dingemans, Kathryn C. Arbour, Matthew D. Hellmann, Margarita Majem, Hira Rizvi, Edouard Auclin, Jeffrey Girshman, Silvia Novello, M. Naigeon, Simona Carnio, Nathalie Cozic, F. Blanc-Durand, Laura Mezquita, Clarisse Audigier-Valette, Peter Sawan, Paolo Bironzo, Nathalie Chaput, Jose Carlos Ruffinelli, Luis Paz-Ares, Patricia Martin-Romano, Ernest Nadal, Melinda Charrier, Wungki Park, Isabel Ruth Preeshagul, David Planchard, Santiago Ponce, Gérard Zalcman, Caroline Rossoni
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
Background: dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non-small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitud
Autor:
Ashkon Rahbari, Wungki Park, Victoria M. Villaflor, Lauren Chiec, Bhoomika Sukhadia, Nisha Mohindra, Victor Wang, Garrett M. Frampton, Sangmin Chang, Jeffrey S. Ross, Si Wang, Zachary R. Chalmers, Siraj M. Ali, Jonathan F. Anker, Vaia Florou, Sang Ha Shin, Jeffrey H. Chuang, Pedro Viveiros, Lee Chun Park, Diana Saravia, Gilberto Lopes, Muhammad Mubbashir Sheikh, Young Kwang Chae, Ethan Sokol, Michael Oh
Publikováno v:
Journal of Thoracic Oncology. 14:1807-1817
Introduction Presently, programmed death ligand 1 is the most commonly used biomarker to predict response to immune checkpoint inhibitors (ICIs) in NSCLC. Owing to its several limitations, there is continuous search for more precise and reliable mark
Autor:
Gilberto Lopes, Wungki Park
Publikováno v:
Clinical Lung Cancer. 20:143-147
There is a rising need for optimal biomarkers to better tailor treatments for patients with cancer in the era of immunotherapy. In addition to programmed death-ligand 1 (PD-L1) and tumor mutation burden (TMB), neutrophil-to-lymphocyte (NLR) is regain
Autor:
Daniel K. Wells, Erik Wennerberg, Benjamin G. Vincent, Christine N. Spencer, Heather M. McGee, Yana G. Najjar, Nils Rudqvist, Randy F. Sweis, Anne Monette, Houssein Abdul Sater, Uqba Khan, Maria Libera Ascierto, Cara Haymaker, Nicholas Tschernia, Praveen K. Bommareddy, Roberta Zappasodi, Vinita Popat, Sara Valpione, Alexandria P. Cogdill, Valentin Barsan, Vesteinn Thorsson, Wungki Park
Publikováno v:
Poster Presentations.
Background Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, long-term benefits are only achieved in a small fraction of patients. Understanding the mechanisms underlying ICB activity is key to improving the efficacy of i
Autor:
Isabel Ruth Preeshagul, Lizza E.L. Hendriks, G. Zalcman, David Planchard, Hira Rizvi, Clarisse Audigier-Valette, Wungki Park, Annapaola Mariniello, Margarita Majem, Silvia Novello, J.P. Pignon, Jose Carlos Ruffinelli, Simona Carnio, Laura Mezquita, Santiago Ponce, Kathryn C. Arbour, Matthew D. Hellmann, Edouard Auclin, Benjamin Besse, Diana Saravia, C. Rossoni, G. Lopes, E. Nadal, Nathalie Chaput, A.M. Dingemans
Publikováno v:
Journal of Thoracic Oncology. 14:S273
Publikováno v:
BMJ case reports. 2018
We describe a rare case of severe autoimmune haemolytic anaemia (AIHA) in the setting of underlying chronic lymphocytic leukaemia receiving intravenous immunoglobulin, history of warm IgG autoantibody and treatment with nivolumab for advanced non-sma
Autor:
Sarita Agte, Young Kwang Chae, A. Rahbari, Diana Saravia, Wungki Park, Michael S. Oh, Gilberto Lopes
Publikováno v:
Journal of Thoracic Oncology. 13:S532
Publikováno v:
Cancer Research. 78:701-701
Background: The dual roles of inflammation in malignancy has been well-described. Neutrophils play a key role in inflammation and carcinogenesis. We previously showed that high NLR may confer resistance to PD1/PDL1 inhibitors in lung cancer patients.